Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 12 Aug 2024
Early recurrence after anti-PD-1/L1 likely to benefit more from anti-CTLA-4, targeted agents
Read Full News1.
Prostate Cancer Treatment Associated With Long-Term Complications
2.
An individual state lost $4.02 billion due to untreated mental illness.
3.
Can Oncotype Predict Recurrence Risk in Older BC Patients?
4.
Is Vitamin D a Key to Better Breast Cancer Survival?
5.
Formaldehyde Causes More Cancer Than Any Other Toxic Air Pollutant
1.
AI in Cancer Diagnostics and Imaging Interpretation
2.
Unlocking the Benefits of Eltrombopag: A Comprehensive Guide
3.
Exploring the Role of Fecal Leukocytes in Intestinal Health
4.
The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting
5.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
5.
Navigating the Complexities of Ph Negative ALL - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge